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I.
Abstract
This paper summarizes the author’s attempt to understand the role and the activist eﬀorts of the Public
Citizen’s Health Research Group under the direction of Sidney Wolfe in the context of the American con-
sumer movement. This understanding is gained (1) by performing some historical analyses and (2) by doing
1a miniature case study. The historical analyses involved research in the history of the consumer activist
movement and then a formulation and threading of some of the major recurrent themes in the consumer
movement. The main themes uncovered and discussed were: (1) a general skepticism towards advertise-
ments, (2) the signiﬁcant role of women in the movement, (3) the ideology that more regulation is better
regulation, and (4) the general connection of the movement with contemporary social reform movements.
Finally, a case study was done. This involved obtaining, organizing and analyzing approximately 85 pri-
mary source documents, which consisted of published letters, petitions, testimonies and various other papers
produced by the Health Research Group during the 1997-2002 time period. The methodology for the case
study is presented in this paper, as are four interesting trends about risk/beneﬁt analysis, what constitutes
“research” and the relationship between authorship and credibility. At the end of the paper, I make some
concluding remarks about remaining questions that still need to be answered.
II.
Introduction
The section provides is a brief overview of the structure of the organizational structure of this paper:
In Part III of this paper, I present an account of the history of the consumer movement and then a discussion
of some of the recurring themes of the consumer movement. The founders of the consumer movement were
determined to protect consumers from the risks of unsafe food, drugs, and other products,1 and were encour-
aged by their peers in the consumer rights movements and has developed in tandem with the environmental
1See Patricia M. Kuntze, Communicating with the FDA: The Oﬃce of Consumer Aﬀairs, 48 Food & Drug L.J. 15 (1993).
2and patients’ rights movements.2 Understanding the history and recurring themes of consumer movements
is crucial for an understanding of the role of the Public Citizen’s Health Research Group.
Having laid out the broad historical context, I then lay out in Part IV a brief history of Public Citizen and its
Health Research Group, which includes an analysis of the group’s functions, purposes and priorities. I also
discuss relevant details about the Director and Co-Founder of the Health Research Group, Sidney Wolfe.
Part V of this paper presents a miniature case study of the Health Research Group by focusing on its ac-
tivism eﬀorts regarding drug safety. I lay out my methodology in Part V.A by discussing how I have chosen
to analyze my primary sources, which consist primarily of 85 published documents from the Public Citizen’s
Health Research Group (amounting to approximately 500 pages of text). These publications include hard-
copies of letters, petitions, statements, testimonies, comments and studies co-authored by Sidney Wolfe and
other leading members of the Health Research Group. In Part V.B, I present the results of my analytical
methods.
Finally, in Part VI, the Concluding Remarks section, I include a few questions (from a list of many) that
have yet to be answered. I hope to obtain answers to these questions in a telephone interview, when and if
possible.
2See id. at 15-16.
3III.
Historical Background
A.
History of the Consumer Movement
It is important to consider the Public Citizen’s Health Research Group in the context of the consumer move-
ment in order to understand its distinct role in history. I have chosen to consider the consumer movement in
terms of two time periods, pre-1960s and post-1960s. The pre-1960s period contains the following two phases
of development, which I emphasize and brieﬂy describe in terms of its relevance to the consumer movement:
development through the Progressive Era (the late 19th and early 20th centuries) and through the New Deal
(the late 1920s and 1930s).3 Indeed, historians of the American consumer movement in the United States
have generally begun with the Progressive Era,4 which is my main rationale for beginning there as well.
Beginning with the 1960s and also the 1970s, the consumer movement went into a new phase and became tied
to larger citizen movements. As Ralph Nader formed the Public Citizen organization in 1971, my description
of this phase will be in more detail.
3However, historian Robert Mayer has chosen to identify three distinct periods of consumer activism, not two: (1) the 1880s
to World War I; (2) the late 1920s to World War II; and (3) the late 1950s to the early 1970s. The main rational for this
seems to be that he has chosen to organize around three particular causes. See generally Robert N. Mayer, The Consumer
Movement: Guardians of the Marketplace (Boston: Twayne Publishers, 1989).
4For example, the three most well known books on the consumer movement in American history begin with the Progressive
Era. See, e.g., Robert N. Mayer, supra note 3; Lorine S. Goodwin, The Pure Food, Drink, and Drug Crusaders, 1879-
1914 (Jeﬀerson, N.C.: McFarland, 1999). Norman I. Silber, Test and Protest: The Influence of Consumers Union
(New York: Holmes & Meier, 1983).
41.
The Consumer Movement Before the 1960s
During the beginning of the Progressive Era, consumers were seen as na¨ ıve and trusting. However, this would
soon change, as it would be during this era that some of the most prominent individual consumer leaders
and consumer advocates began to speak out.5 Women were particularly active in this phase of development
in the consumer movement. Some of the most famous female pioneers were Ellen Swallow Richards, who was
a prominent chemist; Florence Kelley, who founded the National Consumers League at the beginning of the
twentieth century in order to protest the abusive of treatment of laborers6; and, Alice Lakey, who was an
active member of the General Federation of Women’s Clubs and who worked with the Chief of the U.S.D.A.
Bureau of Chemistry, Harvey Wiley, in order to help prompt Congress to enact new legislation that would
protect consumers in the food and drug area.7
One main position of early consumer activist organizations, including the National Consumer’s League, con-
tinued throughout the consumer movement: skeptical stance towards advertising.8 There was a distinct
moral tone to this stance. Indeed, Florence Kelley stated that advertisements were “distinctly not meant to
educate or instruct, but to stimulate, persuade, incite, entice, and induce the indiﬀerent to purchase.”9 Ad-
vertising of the 1920s contained little, if any, real objective information about the actual products. Rather,
advertising merely indicated how a product might bring consumers great “health, happiness [and] com-
5Periodicals also started to warn consumers about the risks of adverse eﬀects to various drugs and the risks of adulterated
foods. See Kuntze, supra note 3, at 16.
6For example, one of the earlier causes of the National Consumers League was to improve the conduction of women and
children who worked for textile manufacturers. See Kathryn K. Sklar, Two Political Cultures in the Progressive Era: The
National Consumers’ League and the American Association for Labor Legislation, in U.S. Women’s History: New Feminist
Essays (Linda Kerber et al., Eds., 1995), 41. [hereinafter Kathryn K. Sklar, Two Political Cultures]
7See Kathryn K. Sklar, Florence Kelley and the Nation’s Work: The Rise of Women’s Political Culture, 1830-1900, 143
(1995). See also Patricia M. Kuntze, Communicating with the FDA: The Oﬃce of Consumer Aﬀairs, 48 Food & Drug L.J. 15,
16 (1993).
8See Kathryn K. Sklar, Two Political Cultures, supra note 6, at 44.
9See Florence Kelley, Aims and Principles of the Consumers’ League, 5 Am. J. Soc. 289, 294 (1899).
5fort.”10 Hence, one of the “point[s] of greatest friction between business and the consumer movement was
advertising.”11
The Pure Food and Drugs Act of 190612 was in large part fueled by the patent medicine and meat scan-
dals publicized by these periodicals and advocates.13 A pattern developed during this time period for what
one might call a chronological life-span of a consumer protest: (1) an occurrence food or drug disaster, (2)
focused research analyzing the disaster, (3) public protest of the causes behind the disaster, (4) responsive
government regulation or legislation.14 Indeed, the pattern seems to have lasted to this day, as a number of
examples indicate.15
During the era of the New Deal, consumers were viewed as targets of the dangers of available goods and
drugs, and there was major reform with more organized action than in previous times. Much of this was
the result of the institution of the Consumer Advisory Board,16 which encouraged the formation of various
grassroots organizations and various publications whose main aim was to test consumer products.17 The ﬁrst
edition of the Consumer Research Bulletin was published during this time.18 This marked the ﬁrst time that
a publication seemed to seek true objectively in testing products, as the Bulletin accepted no advertisements.
Additionally, Consumer Reports, published by the Consumers Union, also attempted to provide consumers
with information about objective product testing.19
The 1920 and 1930s brought about a need for objective scientiﬁc testing to support product approval and
marketing decisions. By the end of the 1930s, various expose-type articles and reports on adulterated foods
10See Stephen Fox, The Mirror Makers: A History of American Advertising and Its Creators (Urbana: University of Illinois
Press, 1997), 95.
11See The Consumer Movement: Lectures by Colston E. Warne (Richard L.D. Morse ed., 1993), 91.
12Pub.L. No. 59-384, 34 Stat. 768 (1906).
13See Kuntze, supra note 1, at 16.
14See id.
15For example, tampon labeling and tamper-resistant packaging laws seem to arise from such a matter. See id.
16This was instituted by the National Recovery Administration. See id.
17See id.
18See id. at 16-17.
19See id. at 17.
6and drug controversies,20 combined with the infamous sulfanilamide tragedy,21 helped to set the scene to
force some major change in food and drug regulation. Accordingly, the Pure Food and Drugs Act of 1906
was revised to create the Food, Drug and Cosmetic Act of 1938.22 Perhaps the most important aspect of
this law was that it forbade the sale of any drug unless the FDA found it to be safe.23 Whatever the most
important impact or aspect of the new law was, the Food, Drug and Cosmetic Act of 1938 deﬁnitely provided
the FDA with greater authority over drug safety and allowed the burden of safety to shift to manufacturers.
2.
The Consumer Movement After the 1960s
The consumer movement in the 1960s and 1970s is generally remembered for the incorporation of consumer
aﬀairs into the national government and an immense distrust in corporations and industry generally.24 The
consumer movement also became responsive to racial minority and the economically disadvantaged gener-
ally.25 For the ﬁrst time in American history, consumer reform became an established ideology, as opposed to
a mere pattern of protest. Ralph Nader has become seen as one of the leaders of this movement, beginning
20See, e.g., Ruth D. Lamb, American Chamber of Horrors: The Truth About Food and Drugs (New York: Farrar & Rinehart,
incorporated, 1936).
21The tragedy is most often referred to as the Elixir of Sulfanilamide Tragedy of 1937, which killed 107 people, most of
whom were infants. A drug company in Tennessee had marketed an antibacterial drug called Sulfanilamide against strep-throat
infections for children as syrup using diethylene glycol (antifreeze) as solvent. Unfortunately, the drug was never tested for
safety, because it had not been required by the FDA to do so. Therefore, it was not discovered that the solvent was lethal until
after the drug was sold. For a detailed account of the tragedy and its aftermath, see James H. Young, Three Southern Food
and Drug Cases, The Journal of Southern History, Vol. 49, No. 1. (Feb., 1983), 3-36. See also Henry A. Wallace, Report of the
Secretary of Agriculture, on Deaths Due to Elixir-Sulfanilamide-Massengill (Senate Documents, 75 Cong., 2 Sess., No. 124,
Serial 10247, Washington, 1937), 2-3; George M. Burditt, Overview of the Last 50 Years: The History of Food Law, 50 Food
& Drug L.J. 197 (1995).
22Pub.L. No. 75-717, 52 Stat. 1040 (1938), as amended 21 U.S.C. § § 301 et seq. (1988).
23See id.
24See Kuntze, supra note 1, at 17.
25This was likely due to the inﬂuence of the civil rights movement during this time. See id.
7with the gathering of “Nader’s Raiders,” which was a network of activists who held great skepticism for
corporate America.26 Many other new consumer organizations were also formed,27 reﬂecting the widespread
idea that not only enactment, but also strict enforcement, of legislation was needed in order to reduce risk
to dangers to consumers.
Like the earlier eras of the consumer movement, activists complained about manipulative advertising and
the existence of unsafe products,28 and the occurrence of a drug scandal helped to force legislative change.29
Ultimately, however, historians say that the consumer movement in the 1960s and 1970s is remembered
for the eﬀorts and activism of Ralph Nader.30 Nader was initially known for his tirade against General
Motors. He argued that the company, along with other American car manufacturers, had misled the public
by convincing the public that automobile safety was an issue associated with the behavior of drivers and the
design of highways, as opposed to the design of the automobile itself.31 Nader published his ideas in 1965
in the form of a 365-page book, describing in detail numerous safety problems with the Chevrolet Corvair
that stemmed from the car’s design defects.32 This book has since become known as “an indictment of the
entire automobile industry, and by extension other giant corporations, for ignoring the consumer’s desire for
[safety].”33 Moreover, it seems to have had the landmark eﬀect of mobilizing consumers into a formidable
political and social force.34
26See id.
27These included the American Council on Consumer Interests, the Consumer Federation of America, and the Alliance for
Consumer Protection. See id.
28See Robert N. Mayer, supra note 3, at 26-27.
29In the 1960s, a drug called thalidomide was marketed to pregnant women in Great Britain and West Germany, which
resulted in numerous birth defects. This resulted in stricter drug regulations in the United States. See id., at 26-27.
30See id., at 26-30.
31See Lucy B. Creighton, Pretenders to the Throne: The Consumer Movement in the United States (Lexington,
MA: Lexington Books, 1976), 28.
32Ralph Nader, Unsafe at Any Speed: The Designed-In Dangers of the American Automobile (New York, Grossman,
1965).
33See Robert N. Mayer, supra note 3, at 28.
34See id. In the end, it also had the immediate and tangible eﬀect of helping to support Nader’s organization from a monetary
standpoint. Dismayed with Nader’s book, General Motors tried to undermine Nader’s credibility in various ways. Nader turned
around and sued General Motors for invasion of privacy and won a half-million dollar settlement, which he then used to support
his organization. See Lucy B. Creighton, supra note 31, at 52. General Motors’ attempt to discredit Nader was unsuccessful,
as his reputation remained intact. Indeed, it would have been hard to ﬁnd any conﬂicts of interest, at least ﬁnancially, because
of Nader’s choice to live a “poor man’s” lifestyle. He did not own any automobile, resided in a low-rent district, and had no
8After 1965, in addition to private manufacturers, Nader and his gathering of followers (the “Nader Raiders”)
also began to point its ﬁngers at federal regulatory agencies for not protecting consumers. The FDA was
one of the many agencies targeted. Nader asserted that these agencies were not properly carrying out and
enforcing statutes.35 In particular, the most popular allegations against federal agencies were that they were
(1) inactive and (2) improperly inﬂuenced by the businesses that they were supposed to be regulating.36
The latter allegation is central to understanding one of the main philosophies behind Nader’s leadership in
the consumer movement. In particular, Nader views the federal government and its regulations as crucial
for counteracting the evils of the large corporations in America who wield considerable power because of
their market and economic status.37 In sum, however, Nader played a central role in creating a social and
political atmosphere that would foster the creation of a variety of consumer protection legislation.38 Indeed,
the creation of the Consumer Product Safety Commission can be seen as a culmination of Nader’s eﬀorts
and one of the high points of the 1970s for the consumer movement.39
There is some current debate about the current inﬂuence of Nader and his followers. A number of com-
mentators consider Nader and his cause to have entered a dormant phase since the 1980s, with the election
of Ronald Reagan.40 Their main rationale is that the prevailing ideology fostered since the Reagan era
regarding the federal regulatory agencies seems to have been that the regulations produced in the 1960s and
1970s placed needless controls and unwarranted burdens on American businesses that hindered economic
growth and development.41 However, one might still argue that, despite this situation, Nader is probably
far from being shut out of governmental and political inﬂuence entirely. This should not be a diﬃcult task,
real social life. See Mayer, supra note 3, at 29.
35See Robert N. Mayer, supra note 3, at 28-29.
36See id.
37See Lucy B. Creighton, supra note 30, at 54.
38See Robert N. Mayer, supra note 3, at 29.
39See id., at 29-30.
40See id.
41See id.
9given Nader’s eﬀect on the recent 2000 presidential campaign.42
B.
Themes in the History of the Consumer Movement
The brief history of the consumer movement that I have provided in the above section gives an indication
that there are indeed a number of recurring themes in the area of consumer activism. I present four of
these here, which shall be useful to keep in mind with respect to their relationship to the role of the Public
Citizen’s Health Research Group.
1.
Skepticism Towards Advertising
A major theme in consumer movements seems to be the heavy skepticism held towards advertising. The
main gripe of activists over advertising is closely linked to the with the consumer activists’ protests against
big corporations, as advertising demonstrates how a large business may choose to engage in deceptive busi-
ness practices. In essence, activists have felt that advertising has been misleading (either because of false
statements or failure to disclose certain information) and therefore improperly inﬂuences a consumer’s choice
42See Barry Burden, Did Ralph Nader Elect George Bush? An Analysis of the Minor Parties in the 2000 Election [Paper
prepared for presentation at the 2001 meeting of the American Political Science Association], at (last visited February 08, 2002)
http://www.people.fas.harvard.edu/∼burden/minor.pdf.
10preferences so that they purchase a product that is useless, or even harmful, to them. Hence, it seems that
activists would prefer that advertising be completely truthful and that there be less of it.
2.
Association with Women
It is also interesting to note that the consumer movement has been associated primarily with women. Pres-
ident Johnson chose Esther Peterson to be his ﬁrst presidential advisor for consumer aﬀairs, and every
president since then has chosen a women to sit in that position.43 This trend may have originated under
the inﬂuential leadership of Florence Kelley, whose activism was extremely successful in the ﬁght for female
workers. In any case, while one can really only speculate regarding what really has kept women involved in
the movement, what matters is that the woman’s voice in the consumer activism was and remains inﬂuential.
43See Robert N. Mayer, supra note 3, at 28. Peterson was replaced by Betty Furness. Then, Nixon appointed Virginia
Knauer, who continued in this position during the Ford and Reagan administrations. When Carter came to oﬃce, he chose
Peterson to resume her old post. Then, Bonnie G. Hill served during the Bush Administration. See United States Government
Manual 1990-1991 287 (1990). Leslie L. Byrne served during the Clinton administration. See United States Government Manual
1997-1998 263 (1997).
113.
More Regulation is Better Regulation
Another trend in the history of consumer activism seems to be the consumer movement’s desire always to
regulate more. In other words, it seems that the remedy for counteracting big business is to have “bigger”
(or, rather, more) regulations. There has never been any kind of push towards de-regulation, and it does
not seem like any consumer activist group would currently make such a move.
4.
Connection with Contemporary Social Reform Movements
Finally, it seems that the most memorable and inﬂuential events in consumer activism have been associated
with or at least coinciding with larger periods of social reform. For example, the ﬁrst two “phases” of
signiﬁcant activism in American history seemed to have occurred during the Progressive Era and then the
New Deal. The changes in the 1960s and 1970s also seemed to ride the spirit of the social movement during
that time as well, which challenged the status quo and held skepticism about businesses and corporate
America.
It is also interesting to note that the American consumer movement has been in large part a reaction, or,
rather, deﬁance against large businesses and corporations. In particular, consumer activist leaders, such
as Kelley and Nader, sought to unify people in order to create a larger collective group that would be
able to battle against the economic power and political inﬂuence of large businesses. Protests against large
12corporations and petitions to the federal regulatory agencies centered on the theory that businesses were
producing unsafe products and engaging in deceptive business practices that could not be eliminated only
by market forces. Hence, given that market forces were insuﬃcient protection, federal regulatory agencies
needed to create better laws, provide more eﬀective enforcement and educate consumers. It became the job
of the activists to remind the regulatory agency of this fact.
IV.
Understanding the Goals of Public Citizen, the Health Research
Group and Stanley Wolfe
A.
The Formation of Public Citizen and Its Current Leadership
Public Citizen was founded in 1971 as a national, nonproﬁt consumer advocacy organization,44 in order
to “ﬁght for openness and democratic accountability in government...and for safe, eﬀective and aﬀordable
prescription drugs and health care.”45 Public Citizen houses six national divisions46: Auto Safety,47 Congress
44Public Citizen does not take any money from the government or from private businesses. See Public Citizen, Protecting
Health, Safety and Democracy, at (last visited February 01, 2002) http://www.citizen.org/about/.
45See id.
46Public Citizen also has oﬃces in Texas and California. The Oakland California Oﬃce focuses upon energy regulation, while
the Texas oﬃce has had a wider variety of concerns covering all of the interests of the national divisions. See id.
47The goal of the Auto Safety division is to ensure “stronger standards for vehicle safety and more sensible regulation of the
trucking industry.” See id.
13Watch,48 Critical Mass Energy and Environmental Program,49 Global Trade Watch,50 Health Research
Group51 and Litigation Group.52 While Ralph Nader is the founder of the organization, he is no longer a
member of the group, having resigned from Public Citizen in 1980 in order to turn his attention to ﬁght
against big insurance companies and various international trade treaties. The current President of Public
Citizen is Joan Claybrook, who was a founding member of the group and had worked with Nader since 1966.
B.
The Purpose and Scope of the Health Research Group: Research-Based
Advocacy and Education
The Public Citizen’s Health Research Group is the “health arm” of Public Citizen. It has one main goal:
to “use[] research and public education to promote system-wide changes in health care policy... [by] en-
gag[ing] in oversight of the government concerning drugs, medical devices, doctors, hospitals, and occupa-
tional health.”53 More speciﬁcally, the members of the Health Research Group aim “to ban or relabel unsafe
or ineﬀective drugs and medical devices and to improve safety standards at work sites”54 by petitioning
and testifying before Congress and federal agencies. The Health Research Group, like the other divisions
of Public Citizen, aims to take preventative measures. Since the Reagan era, it has even more strongly
defended the following position:
48The goal of Congress Watch is to serve generally as a “government watchdog” and to advocate consumer interests before
Congress. See id.
49The Critical Mass Energy and Environment Program works to “protect citizens and the environment from the dangers
posed by nuclear power and seeks policies that will lead to safe, aﬀordable and environmentally sustainable energy.” See id.
50The Global Watch works mainly as an educational body in Public Citizen. It aims to inform Americans about the impact
of economic globalization. See id.
51Instead of giving a footnote description, as with the other divisions listed here, I discuss more thoroughly the goals and
purposes of the Health Research Group in the next section.
52The Litigation Group is a public interest law ﬁrm that litigates cases at all levels of the federal state courts. They aim
to specialize in “federal health and safety regulation, consumer litigation, open government, union democracy, separation of
powers and the First Amendment.” See Public Citizen, Protecting Health, Safety and Democracy, supra note 44.
53See Public Citizen Health Research Group Citizen, at (last visited February 01, 2002) http://www.citizen.org/hrg/.
54See id.
14Preventive regulation is cheaper than after-the-fact ﬁxes; good regulation
avoids expensive litigation and counterproductive blame-laying when prod-
ucts fail; smart regulation results in the development of better and more
eﬃcient products; and above else reasonable regulatory measures save lives
and our environment.55
The Health Research Group is concerned with the following public-health-related matters:56
(1)
drug safety
(2) healthcare delivery
(3) medical devices
(4) food safety
(5) occupational health
These ﬁve matters are not treated equally. It would be diﬃcult to rank exactly the priority of their treat-
ment, even by counting the number of petitions and letters ﬁled by the Health Research Group currently
on record. This is in part due to the fact that the Health Research Group’s current records for all non-drug
concerns seem to have incorrect time gaps, even up to a length of years. For example, between June of
1992 and April 2001, there seemed to be no letters or petitions on ﬁle regarding the issue of food safety.57
However, having provided that caveat, I provide the following chart:
56The web site for the Health Research Group seems to list these categories as informal sub-divisions. See Public Citizen
Health Research Group Citizen, at (last visited February 01, 2002) http://www.citizen.org/hrg/.
57This was based on a thorough library and Internet search, in addition to a phone call to Public Citizen at their Washington,
D.C. oﬃce location. While the discussion in this paper focuses upon drug safety, I have also compiled a list of all documents
related to food safety for future research and for reader’s interest. See Appendix B: List of Health Research Group
Publications and Documents Related to Food Safety.
15Subdivision Number of Publications58
Drug
Safety
501
Healthcare Safety 486
Occupational
Health
270
Medical Devices 182
Food
Safety
172
From this informal compilation, it does seem that drug safety seems to garner the most attention for the
Health Research Group.
A look at a list of what the Health Research Group considered as its achievements also indicate that drug-
related activism is likely to be its central focus. The following list is taken from a recent publication from
the Health Research Group, in which it described itself as a “major participant” towards success in these
matters:59
Success Type
58“Publication” refers to the following materials: (1) petitions to all federal government agencies, (2) request letters to various
federal government agencies, foreign government organizations, and other organizations, (3) letters to various scientiﬁc journals,
(4) letters to various newspapers, (5) testimonies before various federal government agencies (primarily the FDA) as well as
Congress, (6) commentaries before various federal agencies, independent commentaries, (7) studies done by the Health Research
Group, and (8) general press releases.
59See e-Letter on Drugs for Serious Psychiatric Illnesses, at (last visited February 13, 2002)
http://www.citizen.org/eletter/aboutus.htm.
16“Requirement
that
as-
pirin
la-
bels
warn
of
the
risk
of
Reye’s
Syn-
drome
in
chil-
dren
and
teenagers”
Drug
Safety
“Banning of Oraﬂex, Tandearil and
Suprofen, three nonsteroidal
anti-inﬂammatory (NSAID) drugs and
Phenformin, an oral diabetes drug”
Drug Safety
17“Urged
suc-
cess-
ful
crim-
i-
nal
pros-
e-
cu-
tion
of
Eli
Lilly
and
SmithK-
line
for
with-
hold-
ing
re-
ports
of
death
and
in-
juries
caused
by
their
drugs”
Drug
Safety
“Banning of cancer-causing Chloroform
in cough medicines and toothpastes”
Drug Safety
18“Recall
of
the
Bjork-
Shiley
heart
valve
which
has
killed
1000
peo-
ple”
Medical
De-
vices
“Withdrawal of the indication of
lactation suppression for the drug
Parlodel”
Drug Safety
“Forcing OSHA to set safer standards
for exposure to cadmium, ethylene
oxide and other chemicals”
Occupational Health
Indeed, only two of the seven in the above “successes list” relate to non-drug matters; the large majority of
the list pertains to drug safety.
Education, to the consumer population, another success touted by the Health Research Group, is done
mainly through publications, such as books and newsletters. The goal of these publications is to help
consumers make informed decisions. At least three books, all on pharmaceutical, published by the Health
Research Group have become bestsellers.60 Additionally, two monthly newsletters, entitled “Health Letter”
and “Worst Pills, Best Pills News”, give consumers information about drug safety.
60See, e.g., Sidney M. Wolfe, Christopher M. Coley, and the Health Research Group, Pills that Don’t Work:
a consumers’ and doctors’ guide to over 600 prescription drugs that lack evidence of effectiveness (New York:
Farrar, Straus & Giroux, 1981); Joel Kaufman, Linda Rabinowitz-Dagi, Joan Levin, Phyllis McCarthy, Sidney Wolfe,
Eve Bargmann, and the Public Citizen Health Research Group, Over-the-Counter Pills That Don’t Work (New
York: Pantheon Books, 1983). Sidney Wolfe, Larry Sasich, Rose-Ellen Hope, and the Public Citizen Health Research
Group, Worst Pills, Best Pills: A Consumer’s Guide to Avoiding Drug-Induced Death or Illness (New York: Pocket
Books, 1999). See Sidney Wolfe, Medical Monitors: Public Health Advocacy Exposes Threats, Educates Consumers, in Public
Citizen: Special Anniversary Issue, 30 Years Protecting Health, Safety & Democracy Since 1971, at (last visited February 02,
2002) http://www.citizen.org/documents/publichealth.pdf.
19Another means of education is through a web site that is maintained by the Health Research Group. The
resources from Health Research Group page on the Public Citizen web site are impressive. It makes available
to the public, the full text of a healthy number of their publications, such as petitions,61 request letters,62
commentaries,63 and press releases.64 Access to the documents on the web are free, although there are a
signiﬁcant number of documents not available through the web and must be ordered by calling Public Citizen
and paying a fee.
C.
Sidney Wolfe, Director of the Public Citizen Health Research
Group
The Public Citizen Health Research Group is headed by Sidney Wolfe, a physician who co-founded the group
with Nader in 1971 and has been with the group since then. Wolfe received his college education in Chem-
istry from Cornell University and received his medical education at Case Western Reserve University School
of Medicine.65 After an internship and residency in internal medicine, completed in 1966, Wolfe worked at
the National Institutions of Health (NIH), where he focused his research on blood clotting and alcoholism.
While he was at NIH, Wolfe attended a meeting of the American Patients Association, which is where he
met Nader. Soon thereafter, Wolfe began advising Nader on health issues and recruiting students to work for
61See, e.g., Sidney Wolfe, Petition to the Food and Drug Administration requesting an immediate ban of all uses of Phenylpropanolamine (PPA) in over-the-counter products.
(10/19/00, Health Research Group Publication # 1542).
62See, e.g., Sidney Wolfe & Larry Sasich, Letter to the Medicines Control Agency, United Kingdom, urging them to require important warnings on labeling of sildenafil/Viagra.
(08/27/98, Health Research Group Publication # 1454).
63See, e.g., Larry Sasich & Sidney Wolfe, Comments on a Food and Drug Administration survey on the status of useful written prescription drug information for patients, requesting that it be redesigned.
(02/29/00, Health Research Group Publication # 1512).
64See, e.g., Sidney Wolfe, Press release challenging the Clinton Administration for announcing new testing requirements for children’s medications but allowing off-label prescribing to children.
(08/13/97, Health Research Group #1423).
65Since 1995, Wolfe has served as an Adjunct Professor of Internal Medicine at the Case Western Reserve University School
of Medicine.
20Nader. When Nader founded Public Citizen in 1971, he asked Wolfe to set up the Health Research Group.
Wolfe has since then been a full-time employee of the Health Research Group as its Director and received a
MacArthur Fellowship in 1990 in recognition of his work there.66
Wolfe currently sees four main problems and issues with drug safety today: 67
1.
There has been insuﬃcient criticism of the FDA in the media (particularly on televi-
sion) by both the current commissioner Jane Henney and her predecessor Michael Friedman.
2. Ninety-two drugs were approved in 1996 and 1997, which is the largest number of drugs ever approved
in a 2-year period by the FDA. Wolfe sees this as clearly the result of an inappropriate lowering the standards
of drug approval.
3. The general enactment of the 1997 Food and Drug Modernization Act, which, Wolfe asserts, favors
drug companies, who helped to craft it.
4. The new, more relaxed requirements for prescription drug television advertising, which, Wolfe claims,
creates a windfall for manufacturers, many of whom can now increase sales using misleading advertising.
In essence, all of these relate to the government being too soft on the FDA
66Wolfe received his MacArthur Fellowship in recognition of his work in the ﬁeld of public health. Since the inception of the
MacArthur Fellows Program in 1978, there have been, in addition to Wolfe, a total of nine other recipients of the fellowship
who were recognized for their contributions to the ﬁeld of public health: Byllye Avery, Mark Harrington, Eva Harris, Donald
Hopkins, Michael Lerner, Aaron Shirley, Ellen Kovner Silbergeld, Wilma Subra and David Werner. Most recipients engaged
in some kind of health care activism work, whether it is local (e.g., chairman of a local health services center), national (head
of an AIDS activist organization) or international (physician/activist organizing a project in Guinea). See Complete List of
MacArthur Fellows, at (last visited January 15, 2002) http://www.macfound.org/ programs/fel/complete list 5.htm.
67See Sidney Wolfe, Medical Monitors: Public Health Advocacy Exposes Threats, Educates Consumers, in Public Citizen:
Special Anniversary Issue, 30 Years Protecting Health, Safety & Democracy Since 1971, at (last visited February 02, 2002)
http://www.citizen.org/documents/publichealth.pdf.
21Finally, Wolfe has continued to advocate the following approach for consumer activism:68
The ﬁrst method involves petitioning...the government – especially the
Food and Drug Administration (FDA) ...– to enforce the health protection
laws they are charged with upholding. In the case of the FDA, this means
gathering enough scientiﬁc data to force the FDA to put a warning label
on a drug or medical device, or, if necessary, to ban the product or other
regulated FDA-regulated substances such as food additives.... The second
means of concern involves providing information to the public so that even
before the government takes the actions, we are requesting the public be
informed about the problem, so that they may use that information to
protect themselves and their families.
This has been the approach of the Public Citizen Health Research Group for the past thirty years.
V.
A Mini-Case Study in the Contemporary History of the Consumer Movement:
Drug Safety and Sidney Wolfe’s Public Citizen’s Health Research Group (1997-
2002)
A.
Methodology
1.
Archival Materials: Primary Sources
I have employed eighty-ﬁve written publications (amounting to roughly 500 page) from the Public Citizen’s
Health Research Group as my main primary archival sources for this study. All the publications are taken
from the time period from April of 1997 to February of 2002, which spans approximately ﬁve years, and all
publications refer to drug safety. I have chosen to study these ﬁve years (1997-2000) for two main reasons:
68See id.
22(1) I wanted to have a real sense of the contemporary history of the Health Research Group with regards
to drug safety as well as a sense of the recent history of the consumer movement generally; (2) I wanted to
have a broad enough data sample in order to get a sense of patterns and trends, if any exist.
There are four main types of publications: letters/petitions, commentaries, statement and testimonies. The
following chart lists all of the main types of publications (in addition to other less numerous types) as well
as the frequency of their occurrence (i.e., the number of times, out of the total 85, that this publication has
appeared during this time period):
Publication Type Frequency of Occurrence
Letters
&
Pe-
ti-
tions
44
- (Oﬃcially titled as “petitions”
- (Letters to regulatory agencies
- (Letters to others, including
international organizations, science
journals and professional associations
7)
24)
13)
Commentaries 14
Testimonies 9
Press
Re-
leases
2
Statements 10
Reports
3
Opinions/Editorials (WA Post) 1
Articles (NEJM) 1
Informal Studies 1
[total 85 publications]
I have created a more detailed chart in Appendix A, which lists all eighty-ﬁve publications in chronological
23order, beginning with the most recent publication from February 14, 2002. For each publication, the chart
gives the names of the authors (ordered in the manner listed in the publication, when applicable), the full
title of the publication (as it appears on the publication) and a brief description of each document (under
the last column “Type of Publication”).
2.
Studies Along Diﬀerent Axes
Because the sample of data that I have been able to obtain is suﬃciently large, I have chosen to study all
85 sources along diﬀerent axes. By “axes,” I mean to refer to diﬀerent factors. For example, it was possible
to read all of the primary sources in order to investigate whether the Health Research Group has changed
any of its major interests (which I found it has not). I was also able to try to ﬁnd patterns according to
authorship by asking the question of whether certain authors have been associated with certain topics or
kinds of publications. I present what I have found to be the more interesting factors and ﬁndings in the next
section.
My process for analysis is best summarized as follows: I made an additional hard copy of all the documents
that I had ordered, so that I would be able to set aside one set of publications in chronological order while
being able to re-group the other set in terms of subject matter or some other criteria. Next, I took one copy
of all of the documents and ﬁrst skimmed through all of it in one sitting. When I read through the documents
a second time, I took notes with the purpose of ﬁlling in summary information about each document into
a chart (Appendix A) in order to begin looking for trends. During the third time I read through the
documents, I pulled out “hot documents” that seemed to belong together either because they belonged
together topically (e.g., they were a series of publications dealing with exactly the same subject matter)
24or because they were expressing similar themes (e.g., how to perform risk/beneﬁt analysis). I left aside
the documents that were not pulled for later reference and then performed textual analysis of the diﬀerent
groups of publications that I had produced. Additionally, I would move documents from one grouping to
another or copy certain publications into another group, if and when necessary.
I would like to note that all articles that I have chosen to analyze for this paper were authored or co-authored
by Sidney Wolfe. My main rationale for this was that these would be the publications that were likely to
be most important to the Health Research Group. Even if another member of the group had done most
of the work, say, for a letter, it would still be logical for Wolfe to co-sign the document as the Director
of the Health Research Group, if the letter was to grab the attention of the reader of the letter. For the
sake of completion, however, I was personally compelled to order all publications and documents from the
Health Research Group that related to drug safety, regardless of whether they were authored or co-authored
by Sidney Wolfe. I found that only ten documents or so lacked Wolfe’s co-signature and that this group of
documents consisted only of statements, commentaries or press releases. Signiﬁcantly, none of the documents
were letters or petitions, as Wolfe had co-signed all letters, even if he was not the ﬁrst-author.
B.
Results of Analysis: Some Interesting Trends
1.
The Deﬁnition of “Research”: What Counts
The name “Health Research Group” and the repeated statement that the group was aiming towards “re-
search-based advocacy” encouraged me to investigate and analyze exactly what the group meant by “re-
search”:
251.
Collecting and Analyzing FDA Data: Most publications were not
thoroughly “researched” in the traditional scientiﬁc sense of the term. The group had not
conducted any experiments or full-blown meta-analyses. A representative publication
demonstrating typical “research” by the Health Research Group was a letter to the FDA
concerning the need to use ultrasound to monitor clinical trial subjects for a particular
drug.69 Not every single experimental or medical claim was backed up with a citation to
an article or paper. Like most of its other publications, it seemed that the letter primarily
discussed a few statistical or scientiﬁc reviews that had been produced by the FDA itself
and that indicated that the drug being discussed had adverse eﬀects. The only cita-
tion that was to an independent research paper was not by any means central to the letter.
2. Reports on Other’s Experimental Research: There were a number of publications that took the form of
a letter to the FDA informing it of one new publication from some refereed scientiﬁc journal that indicated
a mechanism or further proof for some adverse eﬀect of a drug.70 Hence, there was research in the sense
that it took eﬀort to ﬁnd and inform an agency about a study.
3. Informal Studies: The Health Research Group has itself conducted research in the form of informal
surveys. One particular survey of note was a relatively extensive interview study done on the lowering of
drug approval standards, based on the questioning of 53 medical oﬃcers.71 This survey was then cited by
the Health Research Group in an Opinion/Editorial in the Washington Post entitled “Troubling Climate at
the FDA.”72 In another publication, the Health Research Group also cited to information its own newsletter
70See Elizabeth Barbehenn, Peter Lurie & Sidney Wolfe, Letter to the Food and Drug Administration on a study stating a
possible mechanism for the induction of ovarian cysts with the use of tegaserod (Zelmac) ((6/7/01, Health Research Group
Publication #1577).
71See Peter Lurie and Sidney Wolfe, FDA Medical Oﬃcers’ Survey: FDA Medical Oﬀers Report Lower Standards Permit
Dangerous Drug Approvals (11/01/98). See also Larry Sasich and Sidney Wolfe, Comments on a Food and Drug Administration
survey on the status of useful written prescription drug information for patients, requesting that it be redesigned (2/29/00,
Health Research Group Publication # 1512) (referring to its informal survey on patient information leaﬂets being distributed
for ibuprofen, which found that various information was not being included in the leaﬂets).
72See Peter Lurie and Sidney Wolfe, OPED in the Washington Post entitled Troubling Climate at the FDA which discusses
26“Best Pills, Worst Pills” as mounting evidence regarding the adverse eﬀects of dietary supplements.73
4. Newsletters: Of course, an obvious research aspect of the Health Research Group is seen through its
best-selling books and the newsletters on pharmaceuticals, as mentioned in Part III.
5. Explanations as “Research”: A chart depicting the related structures of phenylpropanolamine (PPA),
amphetamine, and ephedrine was used at least four times in order to show the similarities between PPA
and ephredine, which is a toxic chemical.74 The purpose of the chart was to show that one small part of a
compound, if changed, would transform PPA into the dangerous ephedrine. This is a basic chemical concept,
which did not seem to be scientiﬁc proof or “research,” in the spirit of what one would generally think of as
scientiﬁc research. However, this seemed to be presented as such and seems representative of a general trend
found amongst various Health Research Group letters, petitions and statements: explanations of concepts
seemed to be touted as research.
2.
What Counts as “Risk-Beneﬁt Analysis”
The Health Research Group advocates taking into account “the risks as well as the beneﬁts”75 of a drug.
In letters to or other statements before the Food and Drug Administration, the Health Research Group has
employed a risk-beneﬁt analysis to argue that a drug not be approved or be withdrawn. For example, it has
asserted a number of times that, for whatever reason (either because of a drug manufacturer’s or the FDA’s
statements or failure to disclose), beneﬁts were exaggerated, and risks were not disclosed or were downplayed
inappropriately. The following is typical of the kind of language employed:
medical oﬃcers’ opinions of the drug approval process (12/30/98, Health Research Group Publication # 1469).
73See Sidney Wolfe, Testimony before the House of Representatives Committee on Government Reform Hearing on Dietary
Supplements (03/20/01, Health Research Group Publication # 1560) (including a ﬁve-page appendix from “Best Pills, Worst
Pills,” which describes cases of adverse reactions to various dietary supplements).
74See, e.g., Sidney Wolfe, Ben Peck & Frank Clemente Comments on the Prescription Drug User Fee Act (PDUFA)
(01/28/02, Health Research Group Publication #1606).
75See Sidney Wolfe & Larry Sasich,, Testimony before the FDA Arthritis Drugs Advisory Committee on the Nonsteroidal Anti-Inflammatory Drugs Celecoxib and Rofecoxib
(02/08/02, Health Research Group Publication # 1555).
27The beneﬁts of COX-2 inhibitors as far as reducing GI toxicity appear
to have been grossly exaggerated and oversold. Years after the research
on these beneﬁts was done, a rapid accumulation of evidence on risks is
occurring.
The article will then proceed to describe which beneﬁts were exaggerated and which risks were downplayed
or undisclosed.
In one testimony, to show that a drug, Symlin, should not be approved, Sidney Wolfe’s entire presentation
rested on his own version of a risk beneﬁt analysis.76 Wolfe structured his entire talk in the following manner:
“Beneﬁts: ...Risks: ...”. He asserted that the lowering of a certain chemical by a drug, which would have
been a beneﬁt, was in fact quite small in amount compared to the placebo study. Then, he presented various
nervous and gastrointestinal problems, which, according to Wolfe, should have been considered risky enough
to outweigh the minimal beneﬁt.
It is important to note that Wolfe has a speciﬁc notion of what constitutes beneﬁt beyond general eﬃcacy.
In a number of publications, he states explicitly that the beneﬁts must be “unique.” For example, in a letter
to the FDA petitioning for the immediate ban on the antibiotic Trovan, there was the following statement:
TROVAN is another example of a drug with no unique beneﬁts and un-
questionably unique, life-threatening risks.77
Wolfe never spells out this argument in this letter or any other letter or statement.78 However, it seems as
though, while it may not be necessary for risks to be unique or life threatening for a drug to be banned, it is
76See Sidney Wolfe, Testimony before the Food and Drug Administration Endocrine and Metabolic Drugs Advisory Committee Meeting on pramlintide (Symlin), recommending that it not be approved and that no additional clinical trials be done
(07/26/01, Health Research Group Publication #1584).
78See also Larry Sasich & Sidney Wolfe, Statement on the withdrawal of mibefradil/Posicor from the market.
(06/08/98, Health Research Group Publication #1441) (arguing that Posicor should be withdrawn from the market, because
it has not been shown to oﬀer “special beneﬁt” and has been shown to present an “unreasonable risk.”).
28required that the beneﬁt be unique, given the kinds of risks involve. It seems that certain level risks may be
accepted for one situation in which a beneﬁt is unique, but not for another situation in which a drug does
not have a unique beneﬁt.
In a Statement before the FDA advising the withdrawal of troglitazone, Wolfe made an argument that was
a kind of semi-combination of both the “exaggerated beneﬁts” argument in addition to the “uniqueness”
argument: “The drug was...said to have unique advantages ...[but instead] it had a unique type of tox-
icity...” In other words, consumers had been misled into thinking that there were unique beneﬁts, when
instead there were unique risks.
3.
Authorship and Credibility
There did not seem to be deﬁnite patterns in how co-authors were chosen for publication. However, Wolfe
has been more likely co-author than sole author, except in the case where he was presenting a testimony.
In most cases, Wolfe has been joined by Deputy Director Peter Lurie or pharmacology expert Larry Sasich
in letters of all kinds. Additionally, when there has been a petition to the FDA, it almost always co-signed
by the following three authors: Elizabeth Barbehenn, Larry Sasich and Sidney Wolfe. One possible theory
behind this is that each of the three authors covers an area of expertise; Barbehenn possess a research degree
(Ph.D.), Sasich possesses a pharmacology degree (Pharm.D.), and Wolfe is the “physician anchor” (M.D.).
In other words, use of all three people as co-signatories is in a sense pulling out all the stops and showing
the FDA the gravity of the situation. Finally, there is a trend regarding non-Health Research Group co-
signatories: they are employed on an as-necessary basis, depending on the audience of the publication. For
example, a letter to foreign oﬃcials included the signature of a doctor from that country,79 and a letter to
79See, e.g., Sidney Wolfe.& Larry Sasich, Letter to the Therapeutic Products Program in Canada urging them to require
important warnings on the labeling of sildenaﬁl/Viagra, supra note 75.
29senators included the signature of a politician (i.e., Ralph Nader).80
4.
Letters to Organizations in Foreign Countries
Finally, I wanted to note that the letters to foreign countries from the Health Research Group have gone
only to two places: United Kingdom81 and Canada.82 Three letters have gone to the ﬁrst, and one has gone
to the second. There does not seem to be any particular reason for the Health Research Group to choose
these two countries, except that both countries are English-speaking. Two of the four total letters, one to
the United Kingdom and the other to Canada, were almost identical in content and urged both countries to
require warnings on labels for the drug Viagra.83 Both letters referred to adverse eﬀects caused by Viagra
and the current petition to the FDA by the Health Research Group to change the labeling.84 There have
been no other letters of request to any foreign countries ﬁled since the year 2000.
VI.
Concluding Remarks: Continued Curiosity
80See, e.g., (7/28/97) Ralph Nader and Sidney Wolfe, Letter to Senators urging them not to vote for S.830 since it would
roll back Food and Drug Administration protections (07/28/97, Health Research Group Publication # 1421).
81See Sidney Wolfe & Larry Sasich, Letter to the Medicines Control Agency, United Kingdom, urging them to re-
quire important warnings on labeling of sildenaﬁl/Viagra. (8/27/98, Health Research Group Publication #1454); Larry
Sasich & Sidney Wolfe, Letter to the National Institute for Clinical Excellence urging it to reconsider recommenda-
tions concerning Relenza use among people in the United Kingdom.(11/22/00, Health Research Group Publication # 1547);
Letter to the Food and Drug Administration concerning the United Kingdom’s Committee on Safety of Medicine’s recent warning about potentially serious drug interactions between St. John’s Wort and a large number of other drugs.(03/02/00;
Health Research Group Publication # 1513).
82See Sidney Wolfe.& Larry Sasich,. Letter to the Therapeutic Products Program in Canada urging them to require important
warnings on the labeling of sildenaﬁl/Viagra (8/24/98, Health Research Group # 1452).
83See Sidney Wolfe & Larry Sasich, Letter to the Medicines Control Agency, United Kingdom, supra note 74. See also Sidney
Wolfe.& Larry Sasich, Letter to the Therapeutic Products Program in Canada, supra note 75.
84See Sidney Wolfe, Larry Sasich & Elizabeth Barbehenn, Letter to the Food and Drug Administration urging them to
immediately convene an advisory committee to review various serious problems related to the use of sildenaﬁl (Viagra) (8/20/98,
Health Research Group Publication # #1451).
30In late January of 2002, and then in February of 2002, I email and telephoned Public Citizen to request
to have some telephone interview time with Sidney Wolfe or any other consumer activist working in Public
Citizen’s Health Research Group. To date, I have had no response. Perhaps it is because I do not have
an authentic consumer complaint or am not a journalist looking for a good story! In any case, I will try
contacting the Group again in the near future to see whether it might be possible set up some time to speak
with someone in order to ask some questions that are still on my mind, including the following questions (in
no particular order):
1.
When and how does the Health Research Group decide to write a petition or produce any
other publication? (E.g., Is it based on consumer-contact, consumer surveys, journalist
reports, studies, or word of mouth?
2. When the Health Research Group has decided to produce a publication, such as a petition, who actually
writes it?
3. What does Sidney Wolfe spend his time doing? Is he looking for He co-signs many of the letters, but
is he the author?
4. How has Sidney Wolfe viewed himself as a consumer activist in the post-Reagan era?
5. How does the Health Research Group keep in touch with its consumer base? (E.g., does it place adver-
tisements at all? Does it send people out people regularly to do informal ﬁeld surveys? And if so, are they
kept private?)
6. Has Ralph Nader been involved with Public Citizen or any of its divisions since his departure from the
group in 1980? If so, in what way?
317. What does the Health Research Group see as its main focus currently? Is it drug safety? Is food safety
going to be occupying more time in the near future?
8. How large is the Health Research Group? Who are the members in charge of running the group on a
day-today basis?
9. Does the Health Research Group employ any consultants, such as specialists in risk assessment or risk
analysis?
These are just some of the questions that I have yet to answer, but have already tried to answer somewhat,
based upon the documents I was able to obtain. However, if given a chance, I would be thrilled to ask them
directly to Sidney Wolfe one day.
Appendix A: List and Description of Health Research Group Drug
Publications Employed in this Study
No. Authors Publications Description
321 S.
Wolfe
♣
(2/14/02) Direct-To-Consumer Advertising–Education or Emotion Promotion? (HRG Publication #1610)
Article
in
NEJM
(ar-
gu-
ing
that
pro-
mo-
tional
ma-
te-
rial
is
be-
ing
touted
as
ed-
u-
ca-
tional
and
hence
is
mis-
lead-
ing.)
2 S. Wolfe,
Ben Peck and
Frank Clemente
♣
(1/28/02) Comments on: The Prescription Drug User Fee Act (PDUFA) (HRG Publication #1606)
Comment
(pointing out
disturbing
number of drug
withdrawals)
333 A.
Ar-
dati
(Re-
search
As-
so-
ciate)
&
S.
Wolfe.
♣
(1/17/02) Letter to American Medical Association urging their support of HRG petition to the FDA to ban dietary supplements containing ephedrine alkaloids (HRG Publication #1604)
Letter
to
AMA
(point-
ing
out
ad-
verse
ef-
fects
of
the
drug)
4 S. Wolfe ♣
(11/8/01) Letter to HHS Secretary on Pharmaceutical Research & Manufacturers of America Emergency Preparedness Task Force (HRG Publication #1600)
Letter to HHS
(pointing out
that HHS
meetings with
PhRMA are a
violation of
FACA)
345 B.
Wolf-
man
(At-
tor-
ney),
S.
Wolfe,
Pe-
ter
Lurie
(Deputy
Di-
rec-
tor),
A.
Ar-
dati.
♣
(10/15/01) Letter urging the FDA to reject drug industry’s request for liability disclaimer in its withdrawal of products containing phenylpropanolamine (PPA) (HRG Publication #1596)
Letter
to
FDA
(point-
ing
out
that
the
FDA
does
not
have
au-
thor-
ity
to
do
this,
and
com-
pa-
nies
should
not
be
shielded
from
li-
a-
bil-
ity)
6 S. Wolfe ♣
(10/11/01) Statement before the National Academy of Sciences on the Framework for Evaluating the Safety of Dietary Supplements (HRG Publication #1594)
Statement
(pointing out
the burden on
FDA to
demonstrate
harm, as
opposed to
manufacturers)
357 S.
Wolfe
♣
(8/9/01) Letter to HHS that supports a criminal investigation of Schering-Plough based on the possibility that the company knowingly shipped millions of asthma drug inhalers that may not have contained any active ingredients. (HRG Publication #1586)
Letter
to
HHS
(point-
ing
out
the
oc-
cur-
rence
of
cer-
tain
deaths,
which
seem
to
be
as-
so-
ci-
ated
with
the
Scher-
ing
Plough)
8 S. Wolfe ♣
(7/27/01) Statement to the Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee urging them to not approve the drug teriparatide. (HRG Publication #1585)
Statement to
FDA
(pointing out
that FDA data
and various
publications
indicate that
teriparatide
should be not
be approved)
369 S.
Wolfe
♣
(7/26/01) Testimony before the Food and Drug Administration Endocrine and Metabolic Drugs Advisory Committee Meeting on pramlintide (Symlin), recommending that it not be approved and that no addtional clinical trials be done (HRG Publication #1584)
Testimony
be-
fore
FDA
(point-
ing
out
ben-
e-
ﬁts
and
risks
of
pram-
lin-
tide)
10 S. Wolfe ♣
(7/24/01) Testimony before the Subcommittee on Consumer Aﬀairs Hearing, Senate Commerce Committee on Direct-to-Consumer (DTC) Advertising. (HRG Pubication #1583)
Testimony
before Senate
(advocating
regulation of
content of ads
and pointing
out decreased
FDA
enforcement of
drug
advertising)
3711 E.
Bar-
be-
henn
(Re-
search
An-
a-
lyst),
S.
Wolfe
♣
(7/21/01) Letter to the FDA concerning tegaserod (Zelnorm), for constipation-predominant irritable bowel syndrome, and Novartis’ reluctance to use ultrasound monitoring for their clinical trial subjects. (HRG Publication #1582)
Letter
to
FDA
(point-
ing
out
that
there
were
ovar-
ian
cyst
cases
in
clin-
i-
cal
trial
re-
cip-
i-
ents)
12 S. Wolfe ♣
(6/22/01) Comments to the Food and Drug Administration on the proposed rule to revise the format of prescription drug professional product labeling (HRG Publication #1578)
Comments to
FDA
(giving various
suggestions for
how to revise)
13 E.
Bar-
be-
henn
(Re-
search
An-
a-
lyst),
Pe-
ter
Lurie
S.
Wolfe
♣
(6/7/01) Letter to the Food and Drug Administration on a study stating a possible mechanism for the induction of ovarian cysts with the use of tegaserod (Zelmac) (HRG Publication #1577)
Letter
to
FDA
(note
#11)
3814 S. Wolfe,
L. Sasich
♣
(5/24/01) Testimony before the Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee on a petition to relabel doxazosin (Cardura). (HRG Publication #1575)
Testimony
before FDA:
labeling
(proposing
changes as
well)
3915 P.
Lurie,
S.
Wolfe
♣
(5/2/01) Letter in the Journal of the American Medical Association (JAMA) on problems with the Immune Response Corporation’s HIV-1 vaccine study. (HRG Publication #1573)
Letter
in
JAMA
(point-
ing
out
ac-
cu-
sa-
tions
against
the
IRC
for
be-
ing
ac-
cused
of
pre-
vi-
ous
at-
tempts
to
im-
prop-
erly
in-
ﬂu-
ence
the
pre-
sen-
ta-
tion
of
sci-
en-
tiﬁc
data)
4016 E. Barbehenn
(Research
Analyst),
Peter Lurie
S. Wolfe
♣
(5/1/01) Letter to the FDA concerning the unresponsiveness of the agency’s Freedom of Information Oﬃce to our requests (HRG Publication #1572)
Letter to FDA
(includes a
chart which
points out
missing
documents)
17 L.
Sa-
sich,
S.
Wolfe
♣
(4/18/01) Comments on the Food and Drug Adminstration’s proposed rule concerning the disclosure of safety and eﬀectiveness information about unapproved, investigational products–Human Gene Therapy(HRG Publication #1567)
Comments
on
FDA
(dis-
clo-
sure
rules
for
gene
ther-
apy
and
xeno-
transplantation
should
also
ap-
ply
to
all
other
un-
ap-
proved,
in-
ves-
ti-
ga-
tional
prod-
ucts
4118 E. Barbehenn
(Research
Analyst),
Peter Lurie
S. Wolfe
♣
(4/18/01) Letter-Regulatory by Elizabeth Barbehenn, Ph.D. Peter Lurie, M.D., M.P.H. Sidney Wolfe, M.D. Letter to the Food and Drug Adminstration concerning a memo from their Oﬃce of Post-marketing Drug Risk Assessment (OPDRA) that conﬁrms and extends the dangers of the drug Lotronex for irritable bowel syndrome (HRG Publication #1566)
Letter to FDA
(urging FDA
not to put
Lotronex back
on the market
because of
cases of
ischemic colitis
and severe
constipation)
19 L.
Sa-
sich,
S.
Wolfe
♣
(3/26/01) Comments by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Comments on the Food and Drug Administration’s decision to amend regulations regarding public disclosure of information distributed to advisory committee members for their review and consideration (HRG Publication #1562)
Comments
to
FDA
(giv-
ing
rea-
sons
for
why
FDA
should
not
with-
hold
in-
for-
ma-
tion
un-
til
24
prior
to
meet-
ing)
20 E. Barbehenn
(Research
Analyst),
Peter Lurie
S. Wolfe
♣
(3/22/01) Letter/Comments-Regulatory by Elizabeth Barbehenn, Ph.D. Peter Lurie, M.D., M.P.H. Sidney Wolfe, M.D. Letter to the Food and Drug Administration urging that it not approve tegaserod (Zelmac) because of its highly questionable eﬃcacy and its potential to cause ovarian cysts (HRG Publication #1561)
Letter to FDA:
drug approval
(citing various
papers and
also criteria for
safety and
eﬃcacy)
4221 S.
Wolfe
♣
(3/20/01) Testimony-Congressional by Sidney Wolfe, M.D. Testimony before the House of Representatives Committee on Government Reform Hearing on Dietary Supplements.
Testimony
to
Congress
(point-
ing
out
ad-
verse
re-
ac-
tions
to
di-
etary
sup-
ple-
ments)
22 L. Sasich,
S. Wolfe
♣
(3/1/01) Letter by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Request to Deparatment of Health and Human Services to investigate charges against Schering-Plough for possibly knowingly shipping millions of asthma drug inhalers that may not have contained any active ingredient
Letter to HHS
(see also #7;
pointing out
defective drug
inhalers)
4323 P.
Lurie,
S.
Wolfe
♣
(2/22/01) Request by Peter Lurie, M.D., M.P.H Sidney Wolfe, M.D. Request to the Department of Health and Human Services to halt plans for unethical placebo-controlled study of drug for respiratory distress syndrome in Latin America unless it is redesigned to treat all patients
Letter
to
HHS
(point-
ing
out
al-
ter-
na-
tives
to
placebo
and
un-
eth-
i-
cal
na-
ture
of
placebo
trial
for
in-
fants)
24 S. Wolfe, L.
Sasich
♣
(1/7/01) Testimony-Regulatory by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.P.H. Testimony before the FDA Arthritis Drugs Advisory Committee on the Nonsteroidal Anti-Inﬂammatory Drugs Celecoxib and Rofecoxib
Testimony to
FDA
(pointing out
risks and
beneﬁts of
these drugs)
4425 E.
Bar-
be-
henn
(Re-
search
An-
a-
lyst),
Pe-
ter
Lurie
S.
Wolfe
♣
(12/9/00) Letters-Science by Elizabeth Barbehenn, Ph.D. Peter Lurie, M.D., M.P.H. Sidney Wolfe, M.D. Letter in Lancet on Alosetron for irritable bowel syndrome showing data manipulation in a company-sponsored clinical trial.
Letter
in
Lancet
(point-
ing
out
pos-
si-
ble
data
ma-
nip-
u-
la-
tion;
see
also
#11
and
18)
26 L. Sasich, S.
Wolfe
♣
(11/22/00) Letter by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Letter to the National Institute for Clinical Excellence urging it to reconsider recommendations concerning Relenza use among people in the United Kingdom.
Letter to NICE
(pointing out
adverse eﬀects of
Relenza)
27 S.
Wolfe,
E.
Bar-
be-
henn,
L.
Sa-
sich
♣
(10/30/00) Letter-Regulatory by Sidney Wolfe, M.D. Elizabeth Barbehenn, Ph.D. Larry Sasich, Pharm.D., M.P.H. Letter to the Food and Drug Administration updating the number of cases of ischemic coliitis reported in our 8/31/00 petition.
Letter
to
FDA
(point-
ing
out
more
cases
of
col-
i-
tis;
see
also
#11,18,
25)
28 S. Wolfe ♣
(10/19/00) Petition by Sidney Wolfe, M.D. Petition to the Food and Drug Administration requesting an immediate ban of all uses of Phenylpropanolamine (PPA) in over-the-counter products.
Petition to FDA
(pointing out
adverse eﬀects of
PPA; see also #5)
4529 S. Wolfe ♣
(10/19/00) Testimony-Regulatory by Sidney Wolfe, M.D. Testimony before the Food and Drug Administration NonPrescription Drugs Advisory Committee Meeting on Safety Issues of Phenylpropanolamine/PPA.
Testimony
before FDA
(pointing out
adverse eﬀects
of PPA; see
also #5, 28)
30 L.
Sa-
sich
♣
(9/15/00) Comments-Regulatory by Larry Sasich, Pharm. D., M.P.H. Comments before the Food and Drug Administration’s Public Meeting on the Prescription Drug User Fee Act (PDUFA).
Comments
to
FDA
at
meet-
ing
(point-
ing
out
prob-
lems
with
PDUFA;
see
also
#2)
31 E. Barbehenn,
P. Lurie,
L. Sasich,
S. Wolfe
♣
(8/31/00) Petition by Elizabeth Barbehenn, Ph.D. Peter Lurie, M.D., M.P.H. Larry Sasich, Pharm.D., M.P.H. Petition to the Food and Drug Administration to remove Lotronex from the market.
Petition to
FDA
(discussing
safety, eﬃcacy,
See also #11,
18, 25)
4632 E.
Bar-
be-
henn,
P.
Lurie,
L.
Sa-
sich,
S.
Wolfe
♣
(7/15/00) Letters-Science by Sidney Wolfe, M.D. Peter Lurie, M.D., M.P.H. Larry Sasich, Pharm.D., M.P.H. Letter sent to the Lancet on availability of information on thiazolidinediones.
Letter
to
Lancet
(point-
ing
out
that
a
re-
view
of
the
safety
of
a
drug
is
ﬂawed,
be-
cause
it
re-
lied
pri-
mar-
ily
on
stud-
ied
done
by
drug
com-
pa-
nies
in-
stead
of
pub-
lic
sources,
which
are
less
bi-
ased)
4733 S. Wolfe ♣
(7/13/00) Testimony-Regulatory by Sidney Wolfe, M.D. Testimony before the Food and Drug Administration’s Endocrinologic/Metabolic and Non-Prescription Advisory Committee on prescription to over-the-counter switch.
Testimony to
FDA
(discussing risk
assessment and
risk/beneﬁt
analysis for
cholesterol
test)
4834 S.
Wolfe
♣
(6/28/00) Comments-Regulatory by Sidney Wolfe, M.D. Comments at a Food and Drug Administration hearing on switching drugs from prescription to over-the- counter.
Comment
at
FDA
hear-
ing
(pre-
sent-
ing
seven
prin-
ci-
ples
which
should
be
con-
sid-
ered
in
switch-
ing,
in-
clud-
ing
a
risk/beneﬁt
ra-
tio;
spe-
ciﬁc
con-
cerns
about
choles-
terol
drugs;
see
also
#33)
4935 E. Barbehenn,
S. Wolfe
♣
(6/5/00) Letters/Comments:Regulatory by Sidney Wolfe, M.D. Elizabeth Barbehenn, Ph.D. Letter to Center for Drug Evaluation and Research urging the Food and Drug Administration (FDA) to reject the approval of Uprima.
Letter to FDA
(pointing out
adverse eﬀects
to drug and
problems with
trials)
36 S.
Wolfe
♣
(4/24/00) Comments-Regulatory by Sidney Wolfe, M.D. Comments on the Department of Health and Human Services’ Inspector General’s Study of Adverse Event Reporting for Dietary Supplements.
Comments
to
HHS
(point-
ing
out
con-
cerns
with
FDA’s
ad-
verse
re-
ac-
tion
re-
port-
ing
sys-
tem
for
di-
etary
sup-
ple-
ments,
point-
ing
out
ephedrine/PPA
con-
cern;
see
also
#3)
5037 P. Lurie,
L. Sasich,
S. Wolfe
♣
(4/13/00) Report by Larry Sasich, Pharm. D., M.P.H. Peter Lurie, M.D., M.P.H. Sidney Wolfe, M.D. Study of the drug industry’s performance in ﬁnishing required postmarketing research (Phase IV) studies.
Report to FDA
(reporting on a
“meta-study”
that the
authors did,
based on data
from FDA,
showing that
drug
companies are
failing to fulﬁll
Phase 4 trial
commitments)
38 E.
Bar-
be-
henn,
P.
Lurie,
L.
Sa-
sich,
S.
Wolfe
♣
(4/11/00) Letters/Comments:Regulatory by Sidney Wolfe, M.D. Elizabeth Barbehenn, Ph.D. Larry Sasich, Pharm.D., M.P.H. Letter to the Food and Drug Administration/FDA asking for the immediate withdrawal of Propulsid from the market.
Letter
to
FDA
(re-
quest-
ing
with-
drawal
of
drug
from
mar-
ket
based
on
re-
ported
deaths)
39 S. Wolfe ♣
(3/30/00) Testimony-Regulatory by Sidney Wolfe, M.D. Testimony regarding the Food and Drug Administration categorization of morning sickness and leg edema during pregnancy as conditions not diseases which allows dietary supplement manufacturers to promote for these symptoms
Testimony
regarding FDA
(pointing out
that pregnancy
discomfort are
not “diseases”,
and should not
be advertised
as such)
5140 S.
Wolfe
♣
(3/22/00) Letters/Comments-Regulatory by Sidney Wolfe, M.D. Letter to the Department of Health and Human Services urging that they implement and enforce the Code of Ethics for Government Service with regards to Food and Drug Administration scientists.
Letter
to
HHS
(urg-
ing
en-
force-
ment
of
the
code
in
part
be-
cause
of
the
“re-
pres-
sive
at-
mo-
sphere”
at
FDA)
41 S. Wolfe ♣
(3/14/00) Letters/Comments:Regulatory by Sidney Wolfe, M.D. Letter to the Food and Drug Administration requesting a criminal investigation of Warner Lambert/Parke Davis for what appears to be illegally delaying the submission of data known to the company before troglitazone was marketed. (HRG Publication #1515)
Letter to FDA
(pointing out
delay of liver
toxicity data
under after the
drug had been
marketed)
5242 S.
Wolfe,
P.
Lurie
E.
Bar-
be-
henn
♣
(3/7/00) Petition by Sidney Wolfe, M.D. Peter Lurie, M.D., M.P.H. Elizabeth Barbehenn, Ph.D. Petition to the Food and Drug Administration requesting that it immediately require labeling for the diabetes drugs troglitazone (Rezulin), rosiglitazone (Avandia)
Petition
to
FDA
(point-
ing
out
the
dan-
ger-
ous
ef-
fects
of
Rezulin,
pre-
sent-
ing
their
data
re-
view,
ef-
ﬁ-
cacy
con-
cerns,
tox-
i-
c-
ity,
etc.)
43 S. Wolfe
L. Sasich
♣
(3/2/00) Letters/Comments:Regulatory by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.P.H. Letter to the Food and Drug Administration concerning the United Kingdom’s Committee on Safety of Medicine’s recent warning about potentially serious drug interactions between St. John’s Wort and a large number of other drugs.
Letter to FDA
(pointing out the
British studies
and urging that
the FDA not only
change labeling,
but require that
they send out
warnings to
physicians)
5344 L. Sasich,
S. Wolfe
♣
(2/29/00) Letters/Comments-Regulatory by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Comments on a Food and Drug Administration survey on the status of useful written prescription drug information for patients, requesting that it be redesigned.
Comments on
FDA
(pointing out
shortcomings
of FDA survey
design and
presenting the
results of their
own informal
survey)
5445 S.
Wolfe,
G.
Oak-
ley
(Vis-
it-
ing
Pro-
fes-
sor
of
Epi-
demi-
ol-
ogy)
♣
(2/3/00) Letters/Comments:Regulatory by Sidney Wolfe, M.D. Letter to the Food and Drug Administration regarding their ﬁnal regulations on dietary supplements and their deﬁnition of adverse eﬀects of pregnancy.
Letter
to
FDA
(urg-
ing
FDA
not
to
al-
low
di-
etary
sup-
ple-
ment
man-
u-
fac-
tur-
ers
to
cat-
e-
go-
rize
preg-
nancy
dis-
com-
forts
as
“dis-
eases”;
see
also
#39)
5546 P. Lurie,
S. Wolfe
♣
(8/9/99) Editorial-Lay Press by Sidney Wolfe, M.D. Opinion appearing in USA Today concerning the promotion of oﬀ-label uses of drugs.
Letter to
Medical
Journal of
Australia
(arguing that
placebo-
controlled
trials for
Zidovudine in
Asia and
Africa were not
“quicker” and
did not same
more lives than
active
controlled
trials)
47 J.
Sharf-
stein
(Fel-
low
in
Gen-
eral
Pe-
di-
atrics,
Boston
Med-
i-
cal
Cen-
ter),
S.
Wolfe
♣
(8/3/99) Letters/Comments:Regulatory by Joshua Sharfstein, M.D. Sidney Wolfe, M.D. Letter to the Department of Heath and Human Services concerning Pﬁzer’s campaign to counter the Centers for Disease Control recommendations for treatment of ear infections.
Letter
to
HHS
(as-
sert-
ing
that
Pﬁzer
has
launched
a
cam-
paign
to
con-
vince
doc-
tors
to
ig-
nore
CDC’s
rec-
om-
men-
da-
tions
5648 S. Wolfe,
L. Sasich
E. Barbehenn
♣
(6/3/99) Letters/Comments:Regulatory by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.P.H. Elizabeth Barbehenn, Ph.D. Letter to the Food and Drug Administration to immediately ban the antibiotic trovaﬂoxacin (Trovan).
Letter to FDA
(arguing that
Trovan is a drug
with “no unique
beneﬁts and
unquestionably
unique
life-threatening
risks”)
49 L.
Sa-
sich,
S.
Wolfe
♣
(6/1/99) Letters-Lay by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Letter to the Editor in the Washington Post concerning dangerous drug information found on their web site entitled InteliHealth which is associated with Johns Hopkins University.
Letter
(Lay)
to
Wash-
ing-
ton
Post
(point-
ing
out
er-
rors
on
their
web-
site
re-
gard-
ing
var-
i-
ous
drugs)
50 S. Wolfe ♣
(5/11/99) Statement by Sidney Wolfe, M.D. Statement about a Food and Drug Adminstration article in the Journal of the American Medical Association regarding recently withdrawn drugs and the safety of newly approved drugs.
Statement about
FDA
(pointing out that
FDA article failed
to point out
various
dangers/risks of
drugs mentioned
in the article,
which were
approved by the
FDA)
5751 E. Barbehenn,
L. Sasich,
C. Pearson,
S. Wolfe
♣
(4/4/99) Petition by Elizabeth Barbehenn, Ph.D. Larry Sasich, Pharm.D., M.P.H. Sidney Wolfe, M.D. Citizen’s petition with the National Women’s Health Network to the Food and Drug Administration to change the labeling on tamoxifen (Nolvadex).
Petition to
FDA
(pointing out
that tamoxifen
is a carcinogen
and hence the
label should
reﬂect this;
indicate
risk/beneﬁt)
5852 P.
Lurie,
S.
Wolfe
♣
(3/29/99) Letters/Comments-Other by Peter Lurie, M.D., MPH Sidney Wolfe, M.D. Letter to the World Medical Association expressing alarm at athe current Draft Revised Version of the Declaration of Helsinki.
Letter
to
World
Med-
i-
cal
As-
so-
ci-
a-
tion
(ar-
gu-
ing
that
re-
vi-
sions
to
the
Dec-
la-
ra-
tion
are
in-
tended
to
ac-
com-
mo-
date
HIV
trans-
mis-
sion
trial
re-
searchers
who
are
un-
will-
ing
to
be
eth-
i-
cal)
5953 S. Wolfe ♣
(3/26/99) Letters/Comments-Regulatory by Sidney Wolfe, M.D. Statement before the Food and Drug Administration Endocrine and Metabolic Drugs Advisory Committee meeting advising them to withdraw troglitazone from the U.S. Market.
Statement
before the
FDA
(urging
withdrawal of
diabetes drug,
because of
adcerse (toxic)
eﬀects; see also
#41)
6054 L.
Sa-
sich,
S.
Wolfe
♣
(3/23/99) Letters/Comments-Regulatory by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Comments to the Food and Drug Administration on their List of bulk drug substances that may be used in pharmacy compounding.
Comments
to
FDA
(de-
scrib-
ing
the
ef-
ﬁ-
cacy
and
side
ef-
fects
of
29
nom-
i-
nated
bulk
drug
sub-
stances,
many
of
which
have
not
been
tested
for
safety,
and
urg-
ing
that
con-
sumer
be
told
that
the
drugs
that
they
are
re-
ceiv-
ing
have
not
been
tested
for
safety)
6155 S. Wolfe ♣
(2/10/99) Letters/Comments:Regulatory by Sidney Wolfe, M.D. Letter and documents sent to the Food and Drug Administration urging them to immediately recall all lots of Abbokinase because of possible contamination with infectious agents.
Letter to FDA
(reporting that
his interviews
with FDA
oﬃcials show
that the
precursor to a
clot-busting
drug has been
possibly
contaminated,
derived from
kidneys of
aborted
fetuses)
6256 S.
Wolfe
♣
(1/28/99) Letters/Comments-Regulatory by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.PH Statement before the Food and Drug Administration’s Cardiovascular and Renal Drugs advisory committee urging that they not approve dofetilide (Tikosyn) to prevent recurrent arrythmias
Statement
be-
fore
FDA
(point-
ing
out
that
they
have
been
de-
nied
ac-
cess
to
in-
for-
ma-
tion
about
the
safety
and
ef-
ﬁ-
cacy
of
dofetilide
and
that
pub-
lished
lit-
er-
a-
ture
re-
ﬂect
doubt
of
both)
6357 P. Lurie,
S. Wolfe
♣
(1/15/99) Letters/Comments-Other by Peter Lurie, M.D., MPH Sidney Wolfe, M.D. Letter to United Nations Program on HIV/AIDS commenting on their Guidance Document on ethical considerations in international trials of HIV vaccines.
Letter to UN
Program on
HIV/AIDS
(arguing that
the Guidance
document
needs more in
terms of
increased
human
subjects
protection;
discusses
historical
context; see
also #52)
6458 L.
Sa-
sich,
S.
Wolfe
♣
(1/6/99) Letters/Comments:Regulatory by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Letter to the Food and Drug Administration regarding an ad for troglitazone (Rezulin) in a Hispanic publication, El Tiempo Latino, where the beneﬁts are in Spanish and the warnings and risks in English
Letter
to
FDA
(point-
ing
out
the
se-
ri-
ous-
ness
of
the
risks
as-
so-
ci-
ated
with
Rezulin
and
the
un-
ac-
cept-
abil-
ity
of
not
hav-
ing
these
risks
in
Span-
ish)
6559 S. Wolfe,
L. Sasich,
E. Barbehenn
♣
(12/30/98) Letters/Comments:Regulatory by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., MPH Elizabeth Barbehenn, Ph.D. Letter to the Food and Drug Administration concerning a study in the New England Journal of Medicine amplifying our concerns about the safety of cilostazol
Letter to FDA
(pointing out a
NEJM study
which reports
an increased
death rate
associated with
a drug HRG
had urged the
FDA to pull)
6660 P.
Lurie,
S.
Wolfe
♣
(12/30/98) Editorial by Peter Lurie, M.D., M.P.H. Sidney Wolfe, M.D. OPED in the Washington Post entitled Troubling Climate at the FDA which discusses medical oﬃcer’s opinions of the drug approval process.
Opinion
in
the
Wash-
ing-
ton
Post
(re-
ports
the
re-
sults
of
HRG
in-
for-
mal
sur-
vey
of
53
med-
i-
cal
of-
ﬁ-
cers
who
were
dis-
sat-
is-
ﬁed
with
the
drug
ap-
proval
pro-
cess)
6761 S. Wolfe ♣
(12/9/98) Letters/Comments-Regulatory by Sidney Wolfe, M.D. Statement before the Food and Drug Administration before the Food and Drug Administration’s Science Forum on Biotechnology regarding threats to safe and eﬀective regulation of products.
Statement
before FDA
(emphasizes
the importance
of research to
make safe and
eﬀective
regulations)
6862 S.
Wolfe,
L
Sa-
sich
♣
(12/1/98) Letters/Comments-Regulatory by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.P.H. Statement before the Food and Drug Administration’s Arthritis Drugs advisory committee on the nonsteroidal anti-inﬂammatory drug celexocib.
Statement
be-
fore
FDA
(points
out
that
the
drug
at
hand
is
as
ef-
fec-
tive
as
other
ex-
ist-
ing
drugs,
but
has
a
gas-
troin-
testi-
nal
safety
pro-
ﬁle
sim-
i-
lar
to
placebo;
also
dis-
cusses
drug
com-
pa-
nies
mis-
rep-
re-
sen-
ta-
tive
por-
trayal)
6963 P. Lurie
S. Wolfe
♣
(11/1/98) FDA Medical Oﬃcers Survey: Medical Oﬃcers Report Lower Standards Permit Dangerous Drug Approvals.
Report
(informal
survey that
was used in the
letter from
#60 to point
out that lower
standards are
being
permitted for
drug approval)
64 S.
Wolfe,
L.
Sa-
sich,
E.
Bar-
be-
henn
♣
(10/29/98) Press Release by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., MPH Elizabeth Barbehenn, Ph.D. Press Release Concerning FDA’s Approval of Tamoxifen to Reduce incidence of breast cancer in healthy women puts women at risk.
Press
re-
lease
(point-
ing
out
like-
li-
hood
of
in-
crease
of
risk
to
dis-
ease
due
to
tak-
ing
ta-
mox-
ifen;
see
also
#51)
7065 L. Sasich,
S. Wolfe
♣
(9/16/98) Letters/Comments-Regulatory by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. HRG Comments on Section 406(B) of the FDA MODERNIZATION ACT OF 1997.
Comments
(arguing that
the new act
goes against
protecting
consumers and
that what
needs to be
done is to ﬁx
the defective
drug approval
process and
the
postmarketing
safety system)
7166 S.
Wolfe,
L.
Sa-
sich
♣
(8/27/98) Letters/Comments-Other by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.P.H. Letter to the Medicines Control Agency, United Kingdom, urging them to require important warnings on labeling of sildenaﬁl/Viagra.
Letter
to
the
Medicines
Con-
trol
Agency
in
UK
(urg-
ing
UK
to
in-
clude
warn-
ings
about
ad-
verse
ef-
fects
of
Vi-
a-
gra,
which
have
been
omit-
ted
on
Amer-
i-
can
la-
bels)
7267 S. Wolfe,
L. Sasich,
J. Lexchin
♣
(8/25/98) Letters/Comments: Regulatory by Sidney Wolfe, M.D. Letter to the Food and Drug Administration supporting Dr. Robert Misbin concerning a letter he had written to the Washington Post criticizing FDA policies.
Letter to FDA
(supporting an
FDA medical
oﬃcer’s
criticism of
FDA’s
inappropriate
use of
placebos; see
also #60, 63)
7368 S.
Wolfe,
L.
Sa-
sich,
J.
Lexchin
(The
Toronto
Hos-
pi-
tal)
♣
(8/24/98) Letters/Comments-Other by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.P.H. Letter to the Therapeutic Products Program in Canada urging them to require important warnings on the labeling of sildenaﬁl/Viagra.
Letter
to
Canada
(urg-
ing
Canada
to
in-
clude
warn-
ings
about
ad-
verse
ef-
fects
of
Vi-
a-
gra,
which
have
been
omit-
ted
on
Amer-
i-
can
la-
bels
;
see
also
#66)
7469 S. Wolfe,
L. Sasich,
E. Barnehenn
♣
(8/20/98) Letters/Comments-Regulatory by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.P.H. Elizabeth Barbehenn, Ph.D. Letter to the Food and Drug Administration urging them to immediately convene an advisory committee to review various serious problems related to the use of sildenaﬁl (Viagra).
Letter to FDA
(urging a
meeting on
Viagra of its
cardiovascular
advisory
committee,
because of
possible cardio
side eﬀects; see
also #66, 68)
7570 P.
Lurie,
S.
Wolfe,
Ben
Bagdikian
(For-
mer
As-
sist-
ing
Man-
ag-
ing
Ed-
i-
tor
for
Na-
tional
News)
♣
(7/29/98) Letter by Peter Lurie, M.D., M.P.H. Sidney Wolfe, M.D. Letter to USA Today, demanding action against all USA Today employees responsible for the Glaxo Wellcome Special Editionof the paper distributed at an AIDS conference and promoting Glaxo Wellcome.
Letter
to
USA
To-
day
(point-
ing
out
that,
at
a
con-
fer-
ence,
7000
peo-
ple
re-
ceived
a
“spe-
cial
edi-
tion”
of
USA
To-
day,
which
looked
like
a
reg-
u-
lar
is-
sue,
but
it
was
ac-
tu-
ally
an
ad)
7671 S. Wolfe,
L. Sasich
♣
(7/27/98) Petition by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.P.H. Petition to the Food and Drug Administration to ban troglitazone/Rezulin due to its causing several cases of liver failure.
Petition to
FDA
(pointing out
adverse eﬀects
of Rezulin; see
also #42, 58)
72 L.
Sa-
sich,
S.
Wolfe
♣
(7/23/98) Letters/Comments-Regulatory by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Comments on Food and Drug Administration proposed regulation on dissemination of information on unapproved/new uses for marketed drugs, biologics and devices.
Comment
on
FDA
(point-
ing
out
pos-
si-
ble
pub-
lic
ac-
cess
is-
sues
and
ar-
gu-
ing
that
oﬀ-
label
pre-
scrib-
ing
has
dev-
as-
tat-
ing
con-
se-
quences)
7773 L. Sasich,
E. Fuller Torrey,
S. Wolfe
♣
(7/15/98) Report by Larry Sasich, Pharm. D., M.P.H. E. Fuller Torrey, MD Sidney Wolfe, M.D. Report on the International Comparison of Prices of Antidepressant and Antipsychotic Drugs.
Report
(ﬁnding that
acquisition
cost of drugs
in the US was
higher than in
any other
country in N.
America or
Europe)
7874 S.
Wolfe,
L
Sa-
sich
♣
(7/1/98) Petition by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., MPH Elizabeth Barbehenn, Ph.D. Petition to the Food and Drug Administration to change the labeling and other sources of information on sildenaﬁl/Viagra to reﬂect problems with the drug.
Petition
to
FDA
(point-
ing
out
that
men
with
dis-
eases
which
would
have
ex-
cluded
them
from
pre-
approval
ex-
per-
i-
ments
but
who
are
not
ex-
cluded
from
Vi-
a-
gra
use
now;
see
also
#66,
68,
69)
7975 L. Sasich,
S. Wolfe,
A. Zieve
(attorney,
Litigation Group
of Public
Citizen),
P. & B. Christen
(parents of a
child who died
from
drug-induced
arrhythmia)
♣
(6/9/98) Petition by Sidney Wolfe, M.D. Larry Sasich, Pharm.D., M.P.H. Allison Zieve, J.D. Petition to the Food and Drug Administration to immediately stop the distribution of dangerous, misleading prescription drug information to the public.
Petition to
FDA
(pointing out
that, as a
reulst of
unregulated,
misleading,
commercially
produced
written patient
drug
information, a
child and
many others
have died;
petition to
recall or seize
unregulated
information
that is being
distributed
with
prescription
drugs that is
not consistent
with drug’s
FDA approval)
8076 L.
Sa-
sich,
S.
Wolfe
♣
(6/8/98) Statement by Larry Sasich, Pharm. D., MPH Sidney Wolfe, M.D. Statement on the withdrawal of mibefradil/Posicor from the market.
Statement
(point-
ing
out
that
the
drug
has
no
spe-
cial
ben-
e-
ﬁt,
but
has
prob-
lems
which
pose
an
un-
rea-
son-
able
risk
to
con-
sumers)
77 S. Wolfe ♣
(5/28/98) Statement by Sidney Wolfe, M.D. Statement concerning a report by the Center for Science in the Public Interest on threats to antibiotic eﬀectiveness.
Statement
(arguing that
misleading
advertising is
resulting in
dangerous
prescribing of
antibiotics,
which could
lead to
resistance
8178 S.
Wolfe
♣
(11/13/97) Statement by Sidney Wolfe, M.D. Response to the Institute of Medicine’s Report on Halcion.
Statement
on
IOM
(ar-
gu-
ing
that
Hal-
cion
is
more
dan-
ger-
ous
than
the
IOM
study
imp-
ies
and
point-
ing
out
that
the
UK
banned
the
drug)
79 L. Sasich,
S. Wolfe
♣
(10/14/97) Letters/Comments-Regulatory by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Comments on Food and Drug Administration’s Draft Guidance for Industry on direct to consumer advertising.
Comments on
FDA
(arguing that
the current
regulations on
direct to
consumer
advertising do
not protect
consumers
suﬃciently and
are misleading)
8280 L.
Sa-
sich,
S.
Wolfe
♣
(8/21/97) Statement by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Statement on misleading direct-to-consumer advertising by Schering for loratadine (Claritin).
Comments
(point-
ing
out
that
a
drug
com-
pany
vi-
o-
lated
DTC
TV
ad-
ver-
tis-
ing
reg-
u-
la-
tions
only
11
days
af-
ter
they
were
passed)
81 S. Wolfe ♣
(8/13/97) Press Release by Sidney Wolfe, M.D. Press release challenging the Clinton Administration for announcing new testing requirements for children’s medications but allowing oﬀ-label prescribing to children.
Press Release
(pointing out
that requiring
safety and
eﬃcacy for
children does
not protect
children from
oﬀ-label use
problems)
8382 L.
Sa-
sich,
S.
Wolfe
♣
(8/11/97) Letters/Comments-Regulatory by Larry Sasich, Pharm. D., M.P.H. Sidney Wolfe, M.D. Comments supporting the Drug Enforcement Administration’s proposed placement of butorphanol (Stadol and Stadol Nasal Spray) into Schedule IV.
Comments
(point-
ing
out
that
this
new
clas-
si-
ﬁ-
ca-
tion
will
al-
low
con-
sumers
to
con-
sider
its
po-
ten-
tial
ad-
dict-
ing
prop-
er-
ties
as
a
con-
trolled
sub-
stance,
al-
though
this
comes
too
late
for
those
al-
ready
ad-
dicted) 8483 R. Nader,
S. Wolfe
♣
(7/28/97) Letters/Comments: Congressional by Ralph Nader Sidney Wolfe, M.D. Letter to Senators urging them not to vote for S.830 since it would roll back Food and Drug Administration protections.
Letter to
senators
(makes
assertions for
what would
happen if S.830
was signed into
law)
84 S.
Wolfe
♣
(7/17/97) Letters/Comments: Congressional by Sidney Wolfe, M.D. Letter to Senators urging then to vote agains an amendment to S.830 which would make it legal for companies to promote drugs and medical devices for unapproved uses.
Letter
to
sen-
a-
tors
(makes
as-
ser-
tions
for
what
would
hap-
pen
if
S.830
was
signed
into
law;
see
also
#83)
85 S. Wolfe ♣
(4/11/97) Testimony-Congressional by Sidney Wolfe, M.D. Testimony before the Senate Labor and Human Resources Committee on the Food and Drug Administration performance, eﬃciency and use of resources.
Testimony
before Senate
(answers
questions on
PDUFA, FDA
resources and
regulatory
power)
85I.
Appendix B: List of Health Research Group Publications and Doc-
uments Related to Food Safety
No. Publication
1 ♣
(7/19/01) Report submitted to the Department of Agriculture which discusses the lack of systematic sampling of cow brains for Mad Cow Diseae in the U.S. (HRG Publication #1581)
2 ♣
(4/4/01) Testimony before the Consumer Aﬀairs, Foreign Commerce and Tourism Subcommittee concerning Bovine Spongiform Encephalopathy (BSE), otherwise known as Mad Cow Disease (HRG Publication #1563)
3 ♣
(7/6/92) Letter - HRG Letter to Linda Carey, U.S. Department of Agriculture, opposing DOCKET NUMBER 90-011P, allowing radiation of poultry products.
4 ♣
(11/15/90) Statement – Statement before the National Academy of Sciences Commettee on evaluation of USDA streamlined inspection system for cattle.
5 ♣
(1/30/90) Statement – Statement by Public Citizen concerning the proposed ban on RED DYE #3. aﬀects only provisionally listed uses of the dye.
6 ♣
(8/19/87) Transcript/Speech – Transcript of the MACNEIL LEHRER NEWS HOUR which focused on health hype labeling on supermarket food products.
7 ♣
(3/30/87) Comments – On FDA’s proposed rule regarding labeling of cholesterol and fatty acids in food..
8 ♣
(2/28/86) Comments – Object to FDA’s proposal to formalize a new interpretation of the DES PROVISO that would allo the presence of carcinogenic residues in food.
9 ♣
(2/1/86) Report – The other side of the irradiation story.
10 ♣
(1/21/86) Comments – On USDA’s notice of intent to initiate proposed rulemaking regarding requirements for DEFATTE SCRAP TISSUE used in processed meat products.
11 ♣
(8/15/85) Comments – On HHS REPORT of color additive scientiﬁc review panel on carcinogens in food, drug and cosmetic dyes.
12 ♣
(7/12/85) Transcript/Speech – The Macneil/Lehrer New Hour: HOUR: PRESSURING PRETORIA COMDEN AND GREEN: MUSIC MAKERS DANGEROUS DYES
13 ♣
(2/22/85) Lawsuit/Legal Dcmts – Lawsuit against HHS seeking an order which would ban ten widely-used color additives.
86